|Videos|September 12, 2016

Why Should We Start Using Narrow Spectrum Antibiotics?

Kirk Hevener, PharmD, PhD, assistant professor of Biomedical and Pharmaceutical Sciences at Idaho State University, College of Pharmacy, discusses the advantages of narrow spectrum antibiotics.

Kirk Hevener, PharmD, PhD, assistant professor of Biomedical and Pharmaceutical Sciences at Idaho State University, College of Pharmacy, discusses the advantages of narrow spectrum antibiotics.

Interview Transcript (slightly modified for readability)

“By narrowing in on specific organisms and specifically targeting and going after, say, [Streptococcus] mutans in my case, or [Clostridium] difficile, which there [are] a lot of people that are looking at very narrow spectrum C. diff targets, you’re sparing other bacteria in the microbiome, the bulk of all the bacteria you have in your body.

By sparing those other bacteria, you’re not putting selective pressure on those other bacteria to evolve to be resistant to the antibacterials that you are using. So yes, absolutely: narrow spectrum antibacterial use will limit the development of bacterial resistance.”


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.